ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

MPH Mereo Biopharma Group Plc

26.50
0.00 (0.00%)
19 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Mereo Biopharma Group Plc LSE:MPH London Ordinary Share GB00BZ4G2K23 ORD GBP0.003 (REG S)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 26.50 26.00 27.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Mereo Biopharma Share Discussion Threads

Showing 8551 to 8572 of 8575 messages
Chat Pages: 343  342  341  340  339  338  337  336  335  334  333  332  Older
DateSubjectAuthorDiscuss
18/6/2022
11:07
I am although I must admit I'd forgotten all about them. unfortunately the number of shares I hold is quite small. I believe Astra Zeneca are considering a bid for them but may have some competition. According to the Times The company would accept a bid of $5.
sherlockbones
18/6/2022
11:07
I am although I must admit I'd forgotten all about them. unfortunately the number of shares I hold is quite small. I believe Astra Zeneca are considering a bid for them but may have some competition. According to the Times The company would accept a bid of $5.
sherlockbones
18/2/2021
21:29
Anyone still holding these even though they've gone to NYSE?
They have done extremely well since they listed there.

holdbucket
24/12/2020
08:50
Uncle Boggy, my wife and I both have stock and thankfully sitting on our hands has meant we have gained a lot but obviously have the trading & tax issues (Halifax SD). I presume you both have completed the W-8BEN forms? Halifax haven't even mentioned these to us. What are the tax implications?
Importantly, US stocks have done much better in 2020 than over here, is there opinion that they may well go up and up being within that market now?

holdbucket
20/12/2020
20:54
My shares cleared with Eqi but are no longer in my ISA as they only qualify to hold in trading account. If I had sold out would have lost a lot of money, so pleased I have held as now almost back to break even. However not happy at losing ISA allowance & the hassle of extra paperwork & taxes if I sell, will stop complaining if they jump another 50%+ tomorrow 😀
boggy
18/12/2020
16:23
Hi . My shares have now transferred, and can now be traded through HL.
unclechris
18/12/2020
10:47
Hi, has anyone had any feedback on when the converted shares will show up as NASDAQ shares.
Its a real shame we are not able to trade them. Very poor of the company to do this.

unclechris
17/12/2020
23:24
Jeepers what a scum move

Delist from AIM then announce a huge deal

the stigologist
30/11/2020
07:31
Anyone tell me what happens to spread bet positions ?
harleymaxwell
25/11/2020
12:15
Hi I have received a letter from my broker (EQi) saying they will automatically convert my shares held in an ISA with them to ADR's on 30 November. However they can't stay in the ISA so new shares will be put into my trading account. Not sure whether to sell now or just forego the ISA allowance and just sit on them in the hope they increase dramatically....what are others views? No difference in price now between AIM and Nasdaq
boggy
25/11/2020
12:15
Hi I have received a letter from my broker (EQi) saying they will automatically convert my shares held in an ISA with them to ADR's on 30 November. However they can't stay in the ISA so new shares will be put into my trading account. Not sure whether to sell now or just forego the ISA allowance and just sit on them in the hope they increase dramatically....what are others views? No difference in price now between AIM and Nasdaq
boggy
24/11/2020
21:43
Hi, has anyone received any information from their stockbrokers, regarding the transfer of shares to MERO. I contacted HL, and they have no information at all.
unclechris
11/11/2020
09:28
Free money as current price on nasdaq is over 36p.
donmac101
11/11/2020
07:16
RNS issued 11 Nov 20

MEREO ANNOUNCES INTENTION TO CONTINUE LISTING ITS ADSs ON NASDAQ BUT PLANS CANCELLATION OF ADMISSION OF ITS ORDINARY SHARES TO TRADING ON AIM

Exclusive NASDAQ listing should simplify trading and potentially increase liquidity

Cancellation of AIM admission has no impact on UK presence

Last day of trading on AIM will be 17 December 2020.

holdbucket
28/9/2020
12:58
ondon and Redwood City, Calif., September 28, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announces the appointments of two new members to the Company's Board of Directors.

Dr. Brian Schwartz, former Chief Medical Officer of Arqule, Inc. and Dr. Jeremy Bender, former Vice President of Corporate Development at Gilead Sciences, Inc. and recently appointed Chief Executive Officer of Day One Biopharmaceuticals, Inc., will join Mereo's Board of Directors. Drs. Schwartz and Bender bring significant oncology drug development and corporate development experience to Mereo. In addition, in order to maintain the maximum number of board members at nine, Paul Blackburn will be leaving Mereo's Board of Directors after a five-year tenure as a Non-Executive Director. The changes to the Mereo Board will be made with effect from October 1, 2020.

"We are very pleased to strengthen our board of directors at this important stage in Mereo's evolution," said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo. "Brian and Jeremy are industry veterans with deep experience in clinical and corporate development specifically within oncology and rare diseases. Their collective skill sets will be an asset to Mereo as we prepare to advance etigilimab, our anti-TIGIT antibody, into a Phase 1b/2 combination study in the fourth quarter this year and continue to execute on our broader rare disease pipeline strategy."

Peter Fellner, Chairman of the Board of Directors of Mereo, said: "Mereo is entering an exciting new chapter and we are delighted to welcome Brian and Jeremy to our distinguished Board of Directors. On behalf of the Board, we would also like to thank Paul for his contributions over the past five years especially for his leadership as Chairman of the Audit and Risk Committee. He leaves the Board with the Company well financed and in a strong position to execute on our strategy. We wish him the best in his future endeavours."

avsome1968
16/9/2020
08:28
funny old share this . v hard to read
harleymaxwell
25/8/2020
15:21
Massive volume for this share and big buys going through well above ask and price not moving - must be a big seller in the background?
boggy
25/8/2020
14:14
How does it go down?
harleymaxwell
25/8/2020
11:32
3.42$ in the us to buy
harleymaxwell
25/8/2020
11:10
not inching up anymore...

G.

garth
20/8/2020
22:00
inching up
harleymaxwell
19/8/2020
11:48
Mereo BioPharma Group (NASDAQ:MREO) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Mereo BioPharma Group PLC is a biopharmaceutical company. It is focused on development and commercialization of therapeutics for patients with rare diseases. The company’s product pipeline includes BPS-804, MPH-966, BCT-197, BGS-649, Navicixizumab and Etigilimab which are in clinical stage. Mereo BioPharma Group PLC is based in London, United Kingdom.... “

bad gateway
Chat Pages: 343  342  341  340  339  338  337  336  335  334  333  332  Older

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com